CMPS: COMPASS Pathways Plc American Depository Shares Stocks News on September 13, 2025

Compass’ stock slips despite psilocybin trial hitting target

CMPS

Clinical Trials Arena

3 months ago

Compass’ stock slips despite psilocybin trial hitting target

Compass’s Psychedelic Drug to Treat Depression Meets Goal in Trial

CMPS

Bloomberg

3 months ago

Compass’s Psychedelic Drug to Treat Depression Meets Goal in Trial

Compass’ big psychedelic study doesn’t impress investors

CMPS

BioPharma Dive

3 months ago

Compass’ big psychedelic study doesn’t impress investors

CMPS

MT Newswires

3 months ago

Compass Pathways' COMP360 Psilocybin for Depression Treatment Meets Primary Endpoint in Phase 3 Trial

CMPS

Business Wire

3 months ago

Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

Trump Trade: President said to weigh possible U.S. strike against Iran

CMPS

TipRanks

3 months ago

Trump Trade: President said to weigh possible U.S. strike against Iran

Psychedelic advocates hopeful Trump administration will support space, STAT says

CMPS

TipRanks

3 months ago

Psychedelic advocates hopeful Trump administration will support space, STAT says

Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025

CMPS

Newsfile

3 months ago

Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025

CMPS

Zacks

4 months ago

COMPASS Pathways (CMPS) Upgraded to Buy: Here's What You Should Know

CMPS

Business Wire

4 months ago

Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference

Psychedelic: Compass, GH Research, MindMed report quarterly earnings

CMPS

TipRanks

4 months ago

Psychedelic: Compass, GH Research, MindMed report quarterly earnings

CMPS

GuruFocus.com

4 months ago

Compass Pathways PLC (CMPS) Q1 2025 Earnings Call Highlights: Pivotal Phase 3 Trial Milestone ...

CMPS

Business Wire

4 months ago

Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights

CMPS

Business Wire

4 months ago

Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities

CMPS

Business Wire

5 months ago

Compass Pathways to Announce First Quarter Financial Results on May 8, 2025

CMPS

Market Exclusive

5 months ago

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Why Compass Pathways Stock Was a Double-Digit Winner This Week

CMPS

Motley Fool

5 months ago

Why Compass Pathways Stock Was a Double-Digit Winner This Week

Psychedelic: Clearmind completes clinical site initiations for AUD trial

CMPS

TipRanks

5 months ago

Psychedelic: Clearmind completes clinical site initiations for AUD trial

CMPS

Business Wire

5 months ago

Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

CMPS

Business Wire

6 months ago

Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression

Psychedelic: Exclusive talk with biotech company Clearmind Medicine

CMPS

TipRanks

6 months ago

Psychedelic: Exclusive talk with biotech company Clearmind Medicine

Psychedelic: atai Life Sciences, NRx report quarterly results

CMPS

TipRanks

6 months ago

Psychedelic: atai Life Sciences, NRx report quarterly results

CMPS

Business Wire

6 months ago

Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression

CMPS

Business Wire

6 months ago

Compass Pathways to Participate in Stifel Virtual CNS Forum

Compass one of the most compelling stories in neuropsych, says H.C. Wainwright

CMPS

TipRanks

6 months ago

Compass one of the most compelling stories in neuropsych, says H.C. Wainwright

CMPS

Insider Monkey

6 months ago

COMPASS Pathways plc (CMPS): Among the Best Psychedelic Stocks to Buy in 2025

Psychedelic: GH Research, Compass Pathways report earnings results

CMPS

TipRanks

7 months ago

Psychedelic: GH Research, Compass Pathways report earnings results

CMPS

GuruFocus.com

7 months ago

Compass Pathways PLC (CMPS) Q4 2024 Earnings Call Highlights: Strategic Financing and R&D ...

CMPS

Motley Fool

7 months ago

Compass Pathways Plc (CMPS) Q4 2024 Earnings Call Transcript

CMPS

MT Newswires

7 months ago

Stifel Nicolaus Initiates Coverage on COMPASS Pathways With Buy Rating, $11 Price Target

CMPS

Business Wire

7 months ago

Compass Pathways Announces Fourth Quarter and Full-Year 2024 Financial Results and Business Highlights

CMPS

Business Wire

7 months ago

Compass Pathways to Participate in TD Cowen 45th Annual Health Care Conference

CMPS

Business Wire

7 months ago

Compass Pathways to announce fourth quarter and year-end financial results on February 27th, 2025

It's Official: The Senate Will Let Robert F. Kennedy Jr. 'Go Wild' On Health Care

CMPS

Investor's Business Daily

7 months ago

It's Official: The Senate Will Let Robert F. Kennedy Jr. 'Go Wild' On Health Care

RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care.

CMPS

Investor's Business Daily

7 months ago

RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care.

CMPS

Business Wire

7 months ago

Compass Pathways to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

CMPS

Business Wire

8 months ago

Compass Pathways Appoints Steve Levine, M.D., as Chief Patient Officer

CMPS

MT Newswires

8 months ago

Compass Pathways Prices Offering of American Depositary Shares, Pre-Funded Warrants

CMPS

Business Wire

8 months ago

Compass Pathways Announces Pricing of Underwritten Offering

CMPS

MT Newswires

9 months ago

Compass Pathways Shares Will Be Added to Nasdaq Biotechnology Index

CMPS

Business Wire

9 months ago

Compass Pathways to Be Added to the NASDAQ Biotechnology Index (NBI)

Is Your Mind Ready to Consider Investing in Psychedelics Stocks?

CMPS

Motley Fool

9 months ago

Is Your Mind Ready to Consider Investing in Psychedelics Stocks?

CMPS

Business Wire

10 months ago

Compass Pathways to Participate in December Investor Conferences

CMPS

Simply Wall St.

10 months ago

COMPASS Pathways plc (NASDAQ:CMPS) has caught the attention of institutional investors who hold a sizeable 29% stake

Compass Pathways to participate in Stifel 2024 Healthcare Conference

CMPS

GlobeNewswire

10 months ago

Compass Pathways to participate in Stifel 2024 Healthcare Conference

Compass Pathways cuts 30% of workforce on Phase 3 trial delays

CMPS

TipRanks

10 months ago

Compass Pathways cuts 30% of workforce on Phase 3 trial delays

CMPS

GuruFocus.com

10 months ago

Compass Pathways PLC (CMPS) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...

CMPS

Motley Fool

10 months ago

Compass Pathways Plc (CMPS) Q3 2024 Earnings Call Transcript

Compass delays anticipated psilocybin readout, cuts staff

CMPS

BioPharma Dive

10 months ago

Compass delays anticipated psilocybin readout, cuts staff

Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates

CMPS

Business Wire

10 months ago

Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates

Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024

CMPS

Business Wire

a year ago

Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024

CMPS

Business Wire

a year ago

Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit

Compass Pathways to participate in three investor conferences in September

CMPS

GlobeNewswire

a year ago

Compass Pathways to participate in three investor conferences in September

Morgan Stanley Predicts up to 220% Jump for These 2 ‘Strong Buy’ Stocks

CMPS

TipRanks

a year ago

Morgan Stanley Predicts up to 220% Jump for These 2 ‘Strong Buy’ Stocks

More promise for psilocybin in depression but safety remains a concern

CMPS

Clinical Trials Arena

a year ago

More promise for psilocybin in depression but safety remains a concern

FDA Rejection of MDMA Therapy Isn’t End of Psychedelic-Drug Candidates

CMPS

Barrons.com

a year ago

FDA Rejection of MDMA Therapy Isn’t End of Psychedelic-Drug Candidates

COMPASS Pathways to participate in Canaccord Genuity 44th Annual Growth Conference

CMPS

GlobeNewswire

a year ago

COMPASS Pathways to participate in Canaccord Genuity 44th Annual Growth Conference

CMPS

Motley Fool

a year ago

Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Transcript

Compass Pathways announces second quarter 2024 financial results and business highlights

CMPS

GlobeNewswire

a year ago

Compass Pathways announces second quarter 2024 financial results and business highlights

CMPS

Market Exclusive

a year ago

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Compass Pathways to announce second quarter financial results on August 1, 2024

CMPS

GlobeNewswire

a year ago

Compass Pathways to announce second quarter financial results on August 1, 2024

Compass Pathways appoints Lori Englebert as Chief Commercial Officer

CMPS

GlobeNewswire

a year ago

Compass Pathways appoints Lori Englebert as Chief Commercial Officer

Compass Pathways to participate in upcoming H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

CMPS

GlobeNewswire

a year ago

Compass Pathways to participate in upcoming H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Should You Buy the Dip on Compass Pathways Stock?

CMPS

Motley Fool

a year ago

Should You Buy the Dip on Compass Pathways Stock?

Psychedelics Stocks Are Falling After a Shocking Vote at the FDA. Here's What You Need to Know.

CMPS

Motley Fool

a year ago

Psychedelics Stocks Are Falling After a Shocking Vote at the FDA. Here's What You Need to Know.

After FDA setback, psychedelic drugmakers distance themselves from a pioneer

CMPS

Washington Post

a year ago

After FDA setback, psychedelic drugmakers distance themselves from a pioneer

Psychedelic Drug Stocks Plummet On FDA Advisers' Doubts About Ecstasy Candidate

CMPS

The Wall Street Journal

a year ago

Psychedelic Drug Stocks Plummet On FDA Advisers' Doubts About Ecstasy Candidate

These 2 Catalysts Could Soon Send Compass Pathways Stock Soaring

CMPS

Motley Fool

a year ago

These 2 Catalysts Could Soon Send Compass Pathways Stock Soaring

CMPS

Insider Monkey

a year ago

COMPASS Pathways plc (NASDAQ:CMPS) Q1 2024 Earnings Call Transcript

CMPS

Motley Fool

a year ago

Compass Pathways Plc (CMPS) Q1 2024 Earnings Call Transcript

Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights

CMPS

GlobeNewswire

a year ago

Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights

Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder

CMPS

GlobeNewswire

a year ago

Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder

Compass Pathways to announce first quarter financial results on May 8, 2024

CMPS

GlobeNewswire

a year ago

Compass Pathways to announce first quarter financial results on May 8, 2024

Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment

CMPS

GlobeNewswire

a year ago

Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment

Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression

CMPS

GlobeNewswire

a year ago

Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression

Compass Pathways to participate in upcoming 23rd Annual Needham Virtual Healthcare Conference

CMPS

GlobeNewswire

a year ago

Compass Pathways to participate in upcoming 23rd Annual Needham Virtual Healthcare Conference

CMPS

Insider Monkey

a year ago

20 Most Depressed Countries in Asia

Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors

CMPS

GlobeNewswire

a year ago

Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors

10 Alternatives to Antidepressant Medications

CMPS

Insider Monkey

2 years ago

10 Alternatives to Antidepressant Medications

15 Highest Paying Jobs with a Psychology Degree

CMPS

Insider Monkey

2 years ago

15 Highest Paying Jobs with a Psychology Degree

20 Countries with Most Antidepressant Users in the World

CMPS

Insider Monkey

2 years ago

20 Countries with Most Antidepressant Users in the World

CMPS

Insider Monkey

2 years ago

COMPASS Pathways plc (NASDAQ:CMPS) Q4 2023 Earnings Call Transcript

CMPS

Motley Fool

2 years ago

Compass Pathways Plc (CMPS) Q4 2023 Earnings Call Transcript

CMPS

GuruFocus.com

2 years ago

Compass Pathways PLC Reports Increased Annual Net Loss Amid Clinical Advancements

Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights

CMPS

GlobeNewswire

2 years ago

Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights

Penny Power Players: 3 Stocks to Watch in the Microcap Arena

CMPS

InvestorPlace

2 years ago

Penny Power Players: 3 Stocks to Watch in the Microcap Arena

Compass Pathways to participate in upcoming TD Cowen investor conference

CMPS

GlobeNewswire

2 years ago

Compass Pathways to participate in upcoming TD Cowen investor conference

Compass Pathways to announce fourth quarter and year-end 2023 financial results on February 29, 2024

CMPS

GlobeNewswire

2 years ago

Compass Pathways to announce fourth quarter and year-end 2023 financial results on February 29, 2024

Mental Health Mavericks: 3 Stocks Changing the Game

CMPS

InvestorPlace

2 years ago

Mental Health Mavericks: 3 Stocks Changing the Game

Wall Street Says Compass Pathways Could Rise 307%. Here's How It Could Actually Happen.

CMPS

Motley Fool

2 years ago

Wall Street Says Compass Pathways Could Rise 307%. Here's How It Could Actually Happen.

As investors pile into psychedelics, idealism gives way to pharma economics

CMPS

Associated Press Finance

2 years ago

As investors pile into psychedelics, idealism gives way to pharma economics

ELF Beauty, Palantir, Arm Holdings, Chipotle Headline Busy Earnings Calendar

CMPS

Investor's Business Daily

2 years ago

ELF Beauty, Palantir, Arm Holdings, Chipotle Headline Busy Earnings Calendar

Is CAVA Group, Inc. (CAVA) Outperforming Other Retail-Wholesale Stocks This Year?

CMPS

Zacks

2 years ago

Is CAVA Group, Inc. (CAVA) Outperforming Other Retail-Wholesale Stocks This Year?

Keller Williams Agrees to Pay $70 Million to Settle Antitrust Claims

CMPS

The Wall Street Journal

2 years ago

Keller Williams Agrees to Pay $70 Million to Settle Antitrust Claims

Azul is once again recognized by its Successful Capital Optimization Plan concluded in 2023

CMPS

PR Newswire

2 years ago

Azul is once again recognized by its Successful Capital Optimization Plan concluded in 2023

Compass Pathways to participate in upcoming Oppenheimer investor conference

CMPS

GlobeNewswire

2 years ago

Compass Pathways to participate in upcoming Oppenheimer investor conference

Portillo’s Inc. to Announce Fourth Quarter and Full Year 2023 Results on Tuesday, February 27, 2024

CMPS

GlobeNewswire

2 years ago

Portillo’s Inc. to Announce Fourth Quarter and Full Year 2023 Results on Tuesday, February 27, 2024

Portable-Building Companies Strike $3 Billion Deal

CMPS

The Wall Street Journal

2 years ago

Portable-Building Companies Strike $3 Billion Deal

Johnson & Johnson Faces a 1.03% Portfolio Impact in Eaton Vance Worldwide Health Sciences ...

CMPS

GuruFocus.com

2 years ago

Johnson & Johnson Faces a 1.03% Portfolio Impact in Eaton Vance Worldwide Health Sciences ...

CMPS

Business Wire

2 years ago

Latest COMPASS Pathways Plc American Depository Shares (CMPS) News on September 13, 2025

Share on Social Networks: